Robert Rubin Net Worth

The estimated Net Worth of Robert J. Rubin is at least $515 Thousand dollars as of 1 November 2018. Robert Rubin owns over 8,489 units of HeartBeam Inc stock worth over $315,090 and over the last 15 years he sold BEAT stock worth over $0. In addition, he makes $200,093 as Independent Director at HeartBeam Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Robert Rubin BEAT stock SEC Form 4 insiders trading

Robert has made over 4 trades of the HeartBeam Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 8,489 units of BEAT stock worth $150,001 on 1 November 2018.

The largest trade he's ever made was exercising 15,000 units of HeartBeam Inc stock on 12 May 2017 worth over $108,000. On average, Robert trades about 1,131 units every 24 days since 2009. As of 1 November 2018 he still owns at least 140,040 units of HeartBeam Inc stock.

You can see the complete history of Robert Rubin stock trades at the bottom of the page.

Robert Rubin biography

Dr. Robert Joseph Rubin M.D. serves as Independent Director of the Company. Dr. Rubin has been a Distinguished Professor of Medicine at Georgetown University since 2012. Prior to that, he was a Clinical Professor of Medicine at Georgetown University from 1995 to 2012. Throughout his career, Dr. Rubin has also served as President of several healthcare consulting companies, as Medical Director of ValueRx, a pharmaceutical benefits company, as Assistant Secretary for Planning and Evaluation at the Department of Health and Human Services and as an Assistant Surgeon General in the United States Public Health Service. Dr. Rubin serves as a member of the board of directors of Soligenix, Inc. Dr. Rubin is a board certified nephrologist and internist and brings over 30 years of specific experience as a professor, policy maker, clinician and business professional dedicated to the medical profession. His specific experience with the United States Department of Health and Human Services and as Assistant Surgeon General is a unique and invaluable qualification, which lends insight into governmental practice, policy making and regulation. Dr. Rubin’s extensive and diverse background in education, government and business allows him to serve as a resource on a broad spectrum of matters.

What is the salary of Robert Rubin?

As the Independent Director of HeartBeam Inc, the total compensation of Robert Rubin at HeartBeam Inc is $200,093. There are 9 executives at HeartBeam Inc getting paid more, with Joseph Capper having the highest compensation of $4,133,160.

How old is Robert Rubin?

Robert Rubin is 74, he's been the Independent Director of HeartBeam Inc since 2007. There are no older and 17 younger executives at HeartBeam Inc.

What's Robert Rubin's mailing address?

Robert's mailing address filed with the SEC is C/O SOLIGENIX, INC., 29 EMMONS DRIVE, SUITE B-10, PRINCETON, NJ, 08540.

Insiders trading at HeartBeam Inc

Over the last 11 years, insiders at HeartBeam Inc have traded over $23,124,978 worth of HeartBeam Inc stock and bought 31,500 units worth $221,145 . The most active insiders traders include Joseph H Capper, Heather C Getz, and Willem Elfrink. On average, HeartBeam Inc executives and independent directors trade stock every 32 days with the average trade being worth of $55,046. The most recent stock trade was executed by Urioste George De on 6 September 2024, trading 1,674 units of BEAT stock currently worth $3,917.

What does HeartBeam Inc do?

heartbeam developed a mhealth technology that is diagnostically equivalent to a cardiologist reading a patient’s 12 lead ecg and examining the patient. it comprises a credit card size, 12 lead equivalent, ecg device and a cloud-based diagnostic expert system. studies designed by harvard medical school faculty have shown heartbeam performance to be equal or better than world class cardiologists in diagnosing a heart attack. the technology features personalized diagnostic thresholds and novel heart attack ecg markers from which the application can also help cardiologists locate a heart attack on a 3d model of the heart. heartbeam's icardiologist application utilizes artificial intelligence / machine learning to drive continuous improvements of the system's ability to provide patient analysis and improve the solution's predictive properties.

Complete history of Robert Rubin stock trades at HeartBeam Inc and Soligenix Inc

HeartBeam Inc executives and stock owners

HeartBeam Inc executives and other stock owners filed with the SEC include:

• Joseph Capper,
  President, Chief Executive Officer, Director
• Heather Getz,
  Chief Financial Officer, Executive Vice President, Chief Administrative Officer
• Fred Broadway,
  President, BioTel Heart
• Daniel Wisniewski,
  Senior Vice President - Technical Operations
• Kirk Gorman,
  Independent Chairman of the Board
• Rebecca Rimel,
  Independent Director
• Anthony Conti,
  Independent Director
• Joseph Frick,
  Independent Director
• Stephan Rietiker,
  Director
• Robert Rubin,
  Independent Director
• Colin Hill,
  Independent Director
• Tiffany Olson,
  Independent Director
• Laura Dietch,
  Independent Director
• Dr. Branislav Vajdic Ph.D.,
  Founder, CEO & Director
• Richard D. Brounstein,
  Chief Financial Officer
• Manish Wadhwa,
  Chief Medical Officer
• Andrei Stoica,
  Chief Technology Officer
• Dr. Peter J. Fitzgerald FACC, M.D., Ph.D.,
  Chief Medical Officer
• Ken Persen,
  Chief Technology Officer
• Dr. Jon Hunt Ph.D.,
  Exec. VP & Chief Bus. Officer
• Alexei Shvilkin M.D.,
  Chief Medical Officer
• Dr. Dorin Panescu Ph.D.,
  Chief Technical Officer
• Alan Baumel,
  Chief Operating Officer
• Richard M. Ferrari,
  Exec. Chairman
• George Hrenko,
  Senior Vice President
• Stephen Rietiker,
  Director
• Michael Geldart,
  Senior Vice President
• Ronald A Ahrens,
  Director
• Eric N Prystowsky,
  Director
• Peter Ferola,
  SVP & General Counsel
• Kenneth Warwick Iii Nelson,
  Director
• Mark E Strome,
  10% owner
• Michael R Jaff,
  Director
• Willem Elfrink,
  Director
• Marga Ortigas Wedekind,
  Director
• Urioste George De,
  Director
• Richard Ferrari,
  Director
• Jon Patrick Hunt,
  Chief Business Officer
• Richard Brounstein,
  Chief Financial Officer
• Alan Baumel,
  Chief Operating Officer
• Kenneth Harry Persen,
  Chief Technology Officer
• Robert Paul Eno,
  President
• Branislav Vajdic,
  CHIEF EXECUTIVE OFFICER